# A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy

> **NCT07752264** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanjing IASO Biotechnology Co., Ltd.** · enrollment: 27 (estimated)

## Conditions studied

- Refractory Immune-mediated Necrotizing Myopathy

## Interventions

- **DRUG:** Equecabtagene Autoleucel Injection (Eque-cel)

## Key facts

- **NCT ID:** NCT07752264
- **Lead sponsor:** Nanjing IASO Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2030-08-15
- **Final completion:** 2043-08-15
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07752264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07752264, "A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07752264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*